Royalty Pharma (RPRX) Short term Debt (2019 - 2026)

Royalty Pharma has disclosed Short term Debt across 8 years of filings, most recently posting $380.0 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $380.0 million, down 61.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $380.0 million (down 61.95% YoY), and the FY2025 annual result was $380.0 million, down 61.92% from the prior year.
• Short term Debt came in at $380.0 million for Q1 2026 at Royalty Pharma, roughly flat from $380.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $999.4 million in Q2 2025 to a low of $98.6 million in Q1 2023.
• The 5-year median for Short term Debt is $380.0 million (2025), against an average of $582.0 million.
• Across the five-year window, Short term Debt soared 824.19% in 2022 and sank 61.95% in 2026, its largest moves.
• Royalty Pharma's Short term Debt stood at $997.5 million in 2022, then rose by 0.19% to $999.4 million in 2023, then dropped by 0.16% to $997.8 million in 2024, then sank by 61.92% to $380.0 million in 2025, then changed by 0.0% to $380.0 million in 2026.
• The last three Short term Debt figures came in at $380.0 million (Q1 2026), $380.0 million (Q4 2025), and $380.0 million (Q3 2025), per Business Quant data.